MedTrace Logo

Intrathoracic Chemotherapy for TETs With Pleural Spread or Recurrence

NCT05446935 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2022-09-19

No results posted yet for this study

Summary

Hyperthermic intrathoracic chemotherapy (HITOC) offers an additional treatment option for malignant pleural tumors after surgical cytoreduction. Especially it is used to further improve local tumor control in thymic malignancies with pleural spread, who underwent multimodality therapy including surgical resection. A phase II clinical study was conducted to explore the efficacy and safety of surgery followed by HITOC (POD1: DOX, POD2: cisplatin) for thymic epithelial tumors with pleural spread or recurrence.

Conditions

  • Thymic Epithelial Tumor

Interventions

PROCEDURE

HITOC

Doxorubicin(dose: 25mg/m2) + Cisplatin(dose: 50mg/m2).

Sponsors & Collaborators

  • Shanghai Zhongshan Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-01
Primary Completion
2024-11-30
Completion
2025-11-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05446935 on ClinicalTrials.gov